Search Results 291-300 of 16288 for nivolumab

1. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   antibody (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins (dMMR) or is microsatellite instability-high (MSI-H) - Disease ...

2. Clinical trials - Oncology (Medical)

   This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.

3. A Study to Evaluate Mutanome-directed Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   About this study. The purpose of this study is to evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active ...

4. A Study Comparing Temozolomide and Selumetinib for Treating Patients with Metastatic Melanoma of the Eye - Mayo Clinic

   Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more ...

5. Myelodysplastic Syndromes Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Midostaurin may stop the growth of cancer cells ...

6. Clinical trials - Oncology (Medical)

   The purpose of this study is to evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or ...

7. A Study of Pembrolizumab and Ruxolitinib Phosphate for Treating Patients with Metastatic Stage IV Triple Negative Breast Cancer - Mayo Clinic

   Has received prior therapy with pembrolizumab, nivolumab, avelumab, durvalumab. Has received a live vaccine within 30 days of planned start of registration ...

8. A Study Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma - Mayo Clinic

   PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and ...

9. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study - Mayo Clinic

   NOTE: Recent anti-PD1 or anti-PD-L1, such as pembrolizumab, nivolumab, atezolizumab, and durvalumab, is allowed, but the last dose of anti-PD-1 or anti-PD ...

10. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

    ... nivolumab, MEDI36MEDI4376, or GNE PDL1 [MPDL3280A]) All Patients; Aged 18 years or older on the day written informed consent is given. If has brain ...